Plain-English translation of NCT07263139 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to treat catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare inherited heart condition that causes dangerous, irregular heartbeats — especially during physical activity or emotional stress. The medication works by targeting a specific protein in heart cells to help prevent abnormal rhythms. This will be the first time the medication has been given to patients with CPVT, rather than to healthy volunteers.
Current treatments for CPVT, such as beta-blockers and flecainide, don't work well enough for many patients and can cause unwanted side effects or drug interactions. This trial exists to see whether this new treatment might offer a better option for people whose heart rhythms remain dangerously unstable despite taking standard medications.
You likely qualify if…
You likely don't qualify if…
You will visit the study center multiple times over about 6 weeks. During this time, you will take the medication by mouth in three increasing doses — starting at 5 mg daily, then moving to 25 mg daily, then 50 mg daily — with each dose level lasting about 2 weeks. Between dose increases, the study team will monitor your heart rhythm with exercise tests and blood tests to make sure the medication is safe and working. You will also need to avoid strenuous exercise for 24 hours before each study visit.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Norway